ICA Foundation                     LNG IUS                     Projects                     Application

About us

Press release

Our impact

Project Resources

The Population Council Joins Forces with Schering to Establish the International Contraceptive Access Foundation
NEW YORK and BERLIN (4 May 2004) — The Population Council, an international, nonprofit, nongovernmental research organization, and the Schering AG Group [now Bayer Schering Pharma] announced today that its Finnish subsidiary, Schering Oy, has established the International Contraceptive Access (ICA) Foundation. The ICA Foundation will provide selected public-sector organizations with a levonorgestrel-releasing intrauterine system (LNG IUS) on a not-for-profit basis to help serve the needs of women and families in resource-poor settings, primarily in developing countries.

The Foundation will be managed by a board of trustees comprising representatives from the Population Council, several international public organizations, and Bayer Schering. The board members will annually select organizations and programs to which the products will be donated or sold at a reduced price. The first distributions of the LNG IUS are expected to start later this year.

“Both the Population Council and Schering hope that this Foundation will help to increase the availability of this excellent contraceptive method to women with few financial resources,” said Population Council Vice President Sandra Arnold, Director of Corporate Affairs for the organization and President of the ICA Foundation.

“We are proud to be associated with the Population Council and with other very reputable international organizations through the Foundation,” said Matti Urho, Executive Vice President at Schering Oy and member of the board of trustees of the ICA Foundation. “Through the activities of the foundation, more women in developing countries will benefit from this innovative method of contraception.”

The Population Council has developed numerous contraceptive and reproductive health products since its establishment in 1952. In licensing these products to pharmaceutical companies for manufacturing, marketing, and distribution, the Council always includes provisions for public-sector access, thereby making Council-developed products more readily available to women worldwide.

         Board of Trustees         Contact         Disclaimer         Sitemap